uveitis

Advancements and cutting-edge science abound at the XXXV Congress of ESCRSIt will soon be time for the FIL – Feira Internacional de Lisboa in Lisbon, Portugal to open its doors to the ophthalmic community for the 35th Congress of the European Society of Cataract and Refractive Surgeons (ESCRS), taking place between the 7th and 11th October 2017.
Sirolimus shows promise for posterior segment non-infectious uveitisIntravitreal sirolimus 400 mcg (Ospiria, Santen) demonstrated positive results in pivotal trials investigating it as a treatment for non-infectious uveitis of the posterior segment. A New Drug Application is under FDA review.
Ebola may leave retinal scarThe Ebola virus may leave a retinal scar specific to the disease, according to researchers. “The distribution of these retinal scars or lesions provides the first observational evidence that the virus enters the eye via the optic nerve to reach the retina in a similar way to West Nile virus,” said Dr Paul Steptoe of the Royal Liverpool Hospital, in a press release.
New and different therapies emerging through uveitis pipelineLocal therapy plays a significant role in the treatment of uveitis, either as monotherapy or in combination therapy. Alongside a number of pharmacotherapeutic agents, new products and technologies are in development that could expand clinicians’ options and improve outcomes.
Cataract, glaucoma surgery in uveitis patients present added challengesCataract surgery in patients with coexisting uveitis is more challenging than managing either condition alone. Surgeons must answer a different set of questions and consider alternative management strategies, said Debra A. Goldstein, MD, FRSC, professor of ophthalmology and director of the Uveitis Service, Department of Ophthalmology, Northwestern University Feinberg School of Medicine, Chicago.
Managing viral eye infection: What clinicians should knowThough much research is happening in the diagnosis and treatment of viral eye infections, much of it might not be readily apparent to clinicians, explains Todd P. Margolis, MD, PhD.
Why Acanthamoeba diagnosis is often challengingHaving an awareness of current best practices—such as epidemiology, risk factors, signs and symptoms, and tests—can be key to identifying and treating corneal infections.
Adalimumab effective but not a cure for uveitisAdalimumab (Humira, AbbVie), an immunosuppressive biologic therapy, improves the symptoms of noninfectious active uveitis, but causes some adverse events and does not cure the disease, researchers say.
5 intriguing ARVO abstracts about uveitisAt the 2016 Association for Research in Vision and Ophthalmology (ARVO) meeting in Seattle, about 100 uveitis and uveitis-related papers and posters were presented by researchers from around the world. The presentations covered a wide range of research initiatives that are underway to treat–or at least understand how to address–uveitis. Here are five intriguing abstracts of research that were presented at the meeting.
Study tracks clinical use of dexamethasone implant for DMEA 6-month analysis from the REINFORCE study of the dexamethasone intravitreal implant Ozurdex found an average of one- to two-line vision gains and no new safety concerns.